The European Medicines Agency's Committee for Advanced Therapies (CAT) published the minutes of its 18-20 March 2026 meeting on 5 May 2026, detailing discussions on marketing authorisation applications, scientific recommendations, and updates to guidelines for advanced therapy medicinal products (ATMPs). The document outlines the committee's assessment of several ATMPs, including gene therapies and cell-based products, and provides insights into the evolving regulatory landscape for these innovative treatments.
The minutes cover the CAT's review of new marketing authorisation applications and ongoing evaluations. The committee discussed the quality, safety, and efficacy data for a gene therapy targeting a rare genetic disorder, as well as a CAR-T cell therapy for haematological malignancies. In both cases, the CAT provided recommendations for additional data or post-authorisation studies to address specific concerns. The committee also adopted a revised guideline on the development of gene therapy medicinal products, aiming to clarify requirements for non-clinical and clinical data packages.
Policy orientations and trade-offs
The CAT's discussions reflect a balance between fostering innovation and ensuring patient safety. The committee emphasised the need for robust long-term follow-up data for gene therapies due to potential delayed adverse effects, which may increase development costs and time to market for manufacturers. Conversely, the revised guideline introduces more flexibility in early-stage trial designs, potentially accelerating patient access to promising therapies. The trade-off between rigorous evidence requirements and timely patient access remains a central tension in ATMP regulation.
Impact on stakeholders - ATMP developers: The revised guideline and specific recommendations for ongoing applications may require additional investment in long-term follow-up studies, increasing regulatory burden. However, clearer guidance could reduce uncertainty and streamline future submissions. - Patients: Stricter safety monitoring may delay access to new therapies, but ensures that only products with adequate safety profiles reach the market. - EU regulatory bodies: The CAT's work reinforces EMA's role as a central evaluator of ATMPs, but the need for post-authorisation follow-up may strain resources. - Healthcare systems: New ATMPs, if approved, could offer curative treatments for previously untreatable conditions, potentially reducing long-term care costs, but upfront costs may be high.
Expected institutional follow-up
The CAT's recommendations will inform the Committee for Medicinal Products for Human Use (CHMP) in its final opinions on the discussed applications. The revised guideline will be published for public consultation before final adoption. The next CAT meeting is scheduled for April 2026, where further progress on these and other ATMPs is expected.
← Atlas › News › Health & Lifestyle